Press Releases

Date Title
09/30/15
Summary ToggleNeothetics Initiates Study to Evaluate the Safety of LIPO-202 for Body Contouring in Obese Subjects Printer Friendly Version SAN DIEGO , Sept. 30, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the initiation of the safety study, LIPO-202-CL-21, of LIPO-202, the first non-invasive injectable drug
09/28/15
Summary ToggleNeothetics Expands Its Board of Directors With Appointments of Jeffrey Nugent and Hani Zeini Printer Friendly Version SAN DIEGO , Sept. 28, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that it has named Jeffrey Nugent and Hani Zeini to its Board of Directors. Mr. Nugent is a respected business leader who brings a broad range of valuable experiences to Neothetics .
09/21/15
Summary ToggleNeothetics to Present at the OC Summit on Aesthetics and Dermatology Printer Friendly Version SAN DIEGO , Sept. 21, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that George Mahaffey , president and chief executive officer, was selected to present at the Orange
09/08/15
Summary ToggleNeothetics Announces Last Patient Enrolled in LIPO-202 Pivotal Phase 3 Clinical Trials for Reduction of Subcutaneous Abdominal Fat Printer Friendly Version Top-line Data Expected by Year-End SAN DIEGO , Sept. 8, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced completion of enrollment for its two pivotal U.S.
08/13/15
Summary ToggleNeothetics Reports Second Quarter 2015 Financial Results Printer Friendly Version SAN DIEGO , Aug. 13, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the second quarter 2015.
08/06/15
Summary ToggleNeothetics Announces Reaffirmation of Patents and Termination of Reexamination Challenge by United States Patent and Trademark Office Printer Friendly Version SAN DIEGO , Aug. 6, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the reaffirmation of all claims of two of its issued patents by the United States Patent and Trademark
08/06/15
Summary ToggleNeothetics to Release Second Quarter 2015 Financial Results Printer Friendly Version SAN DIEGO , Aug. 6, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will release its second quarter 2015 financial results before the market opens on Thursday, August
06/30/15
Summary ToggleNeothetics Initiates Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 for Body Contouring Printer Friendly Version SAN DIEGO , June 30, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the initiation of the post-treatment safety and duration of effect study, LIPO-202-CL-23, of LIPO-202,
05/14/15
Summary ToggleNeothetics Reports First Quarter 2015 Financial Results Printer Friendly Version SAN DIEGO , May 14, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results for the first quarter 2015. First Quarter 2015 and Recent Corporate Highlights Neothetics
05/07/15
Summary ToggleNeothetics to Release First Quarter 2015 Financial Results, Host Annual Stockholder Meeting Printer Friendly Version SAN DIEGO , May 7, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will release its first quarter 2015 financial results before the market opens on Thursday, May 14,